An Exploratory, Open-label, Single Center Study to Assess the Efficacy of NULOJIX (Belatacept) in Reducing Donor Specific Human Leukocyte Antigen (HLA) Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients

Trial Profile

An Exploratory, Open-label, Single Center Study to Assess the Efficacy of NULOJIX (Belatacept) in Reducing Donor Specific Human Leukocyte Antigen (HLA) Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Belatacept (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2017 Last checked against ClinicalTrial.gov record.
    • 01 Aug 2016 Status changed from recruiting to completed.
    • 13 Feb 2015 Planned End Date changed from 1 May 2015 to 1 May 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top